HBM Partners
Crossover fundZug · Pre-Seed–Late Stage · 5 people tracked
Investment thesis
HBM Partners invests in private and public healthcare companies across venture, growth and buy-out financings. It targets the biopharma, medtech, diagnostics and broader healthcare sectors in Europe and North America, as well as India, China and other emerging markets. The firm supports portfolio companies through all stages of development, aiming to add value through its industry experience and global network. Regulated by FINMA, HBM Partners advises the SIX-listed HBM Healthcare Investments Ltd and several specialised public and private equity funds, and has a track record of over 100 investments resulting in more than 60 trade sales and IPOs.
Source: firm website, verified Aug 3, 2026.
Team · 5 people
from the firm's website & public directories
What they invest in
from 2 of 2 portfolio companiesBiotech ×2Healthtech ×2AI & Machine Learning ×1Deep Tech ×1Medical Devices ×1
HQs:Switzerland×1United States×1
Investments · 2 tracked
founders shown can be your intro pathMonte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets.
AI & Machine LearningBiotechDeep TechHealthtechBoston, US
Markus Warmuth(M.D., Chief Executive Officer)inSharon Townson(Ph.D., Chief Scientific Officer)John Castle(Ph.D., Chief Data and Information Officer)Filip Janku(M.D., Ph.D., Chief Medical Officer)Phil Nickson(Ph.D., J.D., Chief Business and Legal Officer)Magnus Walter(DPhil, Chief Technology Officer)
Co-investorsAisling CapitalVersant VenturesNew Enterprise Associates (NEA)Amzak HealthAvoro Capital AdvisorsGV (Google Ventures)+1 more
Swixx BioPharma is a commercialization partner that acts as the local subsidiary for biopharma, OTC, and medical device companies in markets they choose not to enter directly, handling market access, regulatory, and commercial operations without its own R&D or manufacturing.
BiotechHealthtechMedical DevicesBaar, CH
Co-investorsBain Capital Life SciencesMérieux Equity PartnersSK Capital Partners
Exits · 1
IPOs and acquisitions across the tracked portfolioMonte Rosa TherapeuticsNASDAQ: GLUE
Portfolio news
latest coverage across their companiesFrequently asked questions
- What stage does HBM Partners invest at?
- HBM Partners invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is HBM Partners's typical check size?
- HBM Partners typically writes checks of $5M – $50M.
- What sectors does HBM Partners focus on?
- HBM Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is HBM Partners located?
- HBM Partners is headquartered in Zug, CH.
Co-investors · 8
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
Lilly Asia Ventures (LAV) is a biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto, backing entrepreneurs building companies focused on breakthrough products that treat disease and improve human health.
Firms observed investing alongside HBM Partners, from public investor directories. Shared companies are the overlap with HBM Partners's recorded portfolio.
Similar investors
F-Prime Capital Partners is a venture capital firm whose team of scientists, engineers, physicians, operators, and investors supports companies in scaling and accelerating growth.
Lightstone Ventures is a life sciences venture firm founded in 2012 that invests in biotech and medtech companies, backing founders translating scientific breakthroughs into therapies and medical technologies.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Lumira Ventures is a North American life sciences venture capital firm that partners with mission-driven entrepreneurs to build companies developing and commercializing healthcare products for patients.
Ambix is a healthcare-focused investment firm that provides funding, strategy, and hands-on support to companies developing medical tools and devices, biochemistry-based technologies, digital health applications, and other novel healthcare solutions. It invests across all stages and also builds companies itself.